Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Drug-related mortality in Canada (1984-1994).

Pharmacoepidemiology and drug safety

Mittmann N, Liu BA, Iskedjian M, Bradley CA, Pless R, Shear NH, Einarson TR.
PMID: 15073784
Pharmacoepidemiol Drug Saf. 1997 May;6(3):157-68. doi: 10.1002/(SICI)1099-1557(199705)6:3<157::AID-PDS260>3.0.CO;2-J.

OBJECTIVE: To examine drug-related deaths due to adverse drug reactions between 1984 and 1994.DATA SOURCE: Voluntary reports of deaths due to adverse events as reported to the Adverse Drug Reaction Monitoring Program, Drugs Directorate, Health Protection Branch, Health Canada.METHODS:...

Cite
Mittmann N, Liu BA, Iskedjian M, et al. Drug-related mortality in Canada (1984-1994). Pharmacoepidemiol Drug Saf. 1997;6(3):157-68doi: 10.1002/(SICI)1099-1557(199705)6:3<157::AID-PDS260>3.0.CO;2-J.
Mittmann, N., Liu, B. A., Iskedjian, M., Bradley, C. A., Pless, R., Shear, N. H., & Einarson, T. R. (1997). Drug-related mortality in Canada (1984-1994). Pharmacoepidemiology and drug safety, 6(3), 157-68. https://doi.org/10.1002/(SICI)1099-1557(199705)6:3<157::AID-PDS260>3.0.CO;2-J
Mittmann, N, et al. "Drug-related mortality in Canada (1984-1994)." Pharmacoepidemiology and drug safety vol. 6,3 (1997): 157-68. doi: https://doi.org/10.1002/(SICI)1099-1557(199705)6:3<157::AID-PDS260>3.0.CO;2-J
Mittmann N, Liu BA, Iskedjian M, Bradley CA, Pless R, Shear NH, Einarson TR. Drug-related mortality in Canada (1984-1994). Pharmacoepidemiol Drug Saf. 1997 May;6(3):157-68. doi: 10.1002/(SICI)1099-1557(199705)6:3<157::AID-PDS260>3.0.CO;2-J. PMID: 15073784.
Copy Download .nbib Format: NLM
What doctors should consider before prescribing e-liquids for e-cigarettes.

The Medical journal of Australia

Ween MP, Chapman DG, Larcombe AN.
PMID: 34839531
Med J Aust. 2022 Jan 17;216(1):14-16. doi: 10.5694/mja2.51351. Epub 2021 Nov 28.

No abstract available.

Cite
Ween MP, Chapman DG, Larcombe AN. What doctors should consider before prescribing e-liquids for e-cigarettes. Med J Aust. 2021;216(1):14-16doi: 10.5694/mja2.51351.
Ween, M. P., Chapman, D. G., & Larcombe, A. N. (2022). What doctors should consider before prescribing e-liquids for e-cigarettes. The Medical journal of Australia, 216(1), 14-16. https://doi.org/10.5694/mja2.51351
Ween, Miranda P, et al. "What doctors should consider before prescribing e-liquids for e-cigarettes." The Medical journal of Australia vol. 216,1 (2022): 14-16. doi: https://doi.org/10.5694/mja2.51351
Ween MP, Chapman DG, Larcombe AN. What doctors should consider before prescribing e-liquids for e-cigarettes. Med J Aust. 2022 Jan 17;216(1):14-16. doi: 10.5694/mja2.51351. Epub 2021 Nov 28. PMID: 34839531.
Copy Download .nbib Format: NLM
Screening Anti-inflammatory, Anticoagulant, and Respiratory Agents for SARS-CoV-2 3CL.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion

Caires Silveira E, García-Holgado A, García-Peñalvo FJ.
PMID: 34495950
Rev Invest Clin. 2021 Sep 08; doi: 10.24875/RIC.21000282. Epub 2021 Sep 08.

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), triggers a pathophysiological process linked not only to viral mechanisms of infectivity, but also to the pattern of host response. Drug repurposing is...

Cite
Caires Silveira E, García-Holgado A, García-Peñalvo FJ. Screening Anti-inflammatory, Anticoagulant, and Respiratory Agents for SARS-CoV-2 3CL. Rev Invest Clin. 2021;doi: 10.24875/RIC.21000282.
Caires Silveira, E., García-Holgado, A., & García-Peñalvo, F. J. (2021). Screening Anti-inflammatory, Anticoagulant, and Respiratory Agents for SARS-CoV-2 3CL. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, . https://doi.org/10.24875/RIC.21000282
Caires Silveira, Elena, et al. "Screening Anti-inflammatory, Anticoagulant, and Respiratory Agents for SARS-CoV-2 3CL." Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion vol. (2021). doi: https://doi.org/10.24875/RIC.21000282
Caires Silveira E, García-Holgado A, García-Peñalvo FJ. Screening Anti-inflammatory, Anticoagulant, and Respiratory Agents for SARS-CoV-2 3CL. Rev Invest Clin. 2021 Sep 08; doi: 10.24875/RIC.21000282. Epub 2021 Sep 08. PMID: 34495950.
Copy Download .nbib Format: NLM
What doctors should consider before prescribing e-liquids for e-cigarettes.

The Medical journal of Australia

Ween MP, Chapman DG, Larcombe AN.
PMID: 34839531
Med J Aust. 2021 Nov 28; doi: 10.5694/mja2.51351. Epub 2021 Nov 28.

No abstract available.

Cite
Ween MP, Chapman DG, Larcombe AN. What doctors should consider before prescribing e-liquids for e-cigarettes. Med J Aust. 2021;doi: 10.5694/mja2.51351.
Ween, M. P., Chapman, D. G., & Larcombe, A. N. (2021). What doctors should consider before prescribing e-liquids for e-cigarettes. The Medical journal of Australia, . https://doi.org/10.5694/mja2.51351
Ween, Miranda P, et al. "What doctors should consider before prescribing e-liquids for e-cigarettes." The Medical journal of Australia vol. (2021). doi: https://doi.org/10.5694/mja2.51351
Ween MP, Chapman DG, Larcombe AN. What doctors should consider before prescribing e-liquids for e-cigarettes. Med J Aust. 2021 Nov 28; doi: 10.5694/mja2.51351. Epub 2021 Nov 28. PMID: 34839531.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries